General Information of Drug (ID: DMX0DUH)

Drug Name
MEDI2228 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMX0DUH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Idecabtagene vicleucel DMP1QTS Multiple myeloma 2A83 Approved [3]
Belantamab mafodotin DMBT3AI Multiple myeloma 2A83 Approved [4]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [5]
Teclistamab DMGR8JI Multiple myeloma 2A83 Approved [6]
Ciltacabtagene autoleucel DMU2J7Y Multiple myeloma 2A83 Phase 3 [7]
Bb2121 DMB0UF9 Multiple myeloma 2A83 Phase 2 [8]
LCAR-B38M CAR-T Cell DMQZJNA Multiple myeloma 2A83 Phase 2 [9]
Descartes-08 DM63P1W Multiple myeloma 2A83 Phase 2 [10]
Descartes-11 DM1UO4S Multiple myeloma 2A83 Phase 2 [11]
CART-19/BCMA DMVW1GY Multiple myeloma 2A83 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell maturation protein (TNFRSF17) TTZ3P4W TNR17_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health.
2 A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
6 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
7 ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
10 ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
11 Clinical pipeline report, company report or official report of Cartesian Therapeutics.
12 ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT